Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02283294 · ClinicalTrials.gov registry record · Phase 3
Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
A Phase 3 study, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT02283294: Completed Phase 3 study, sponsored by University of South Florida.
NCT02283294 is a Phase 3 study that has completed, run by University of South Florida. The registered enrollment target is 91 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02283294, a Phase 3 study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.
Interventions
- DRUG Apixaban
- DRUG Warfarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-06 |
| Phase | Phase 3 |
What the finished NCT02283294 record still lists
NCT02283294 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT02283294 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02283294 about?
NCT02283294 is a clinical study titled "Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation". The purpose of this study is to evaluate if Apixaban will decrease the complication of having another stroke for people who have atrial fibrillation if initiated earlier than standard of care.
What is the current status of trial NCT02283294?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2015-04. Estimated completion is 2019-06.
What interventions are being tested in trial NCT02283294?
The interventions under investigation include: Apixaban (DRUG), Warfarin (DRUG).
Who is sponsoring clinical trial NCT02283294?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02283294's enrollment target sits among peer trials
91 1724th of 2000 higher than 277 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia